Better Stock Today Challenge: Energy Transfer Partners vs. Celgene
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.
Energy Transfer Partners takes on Celgene for this first round-robin match up in our search for the better stock today.
Joel South, energy analyst at The Motley Fool, thinks Energy Transfer Partners is a great investment for dividend lovers. The Master Limited Partnership currently distributes a very respectable 6.6% yield, but with strong segment diversification, a proven track record of executing on project backlogs and a built out pipeline infrastructure ready to service U.S. LNG exports, distributable cash flows should continue to pick up for unitholders.
Healthcare Analyst David Williamson believes the number one reason Celgene should win this match is its ability to open new sales possibilities for already approved drugs. By expanding indications, i.e. having drugs used for multiple diseases, management expects to double earnings from 2013 to 2017. Headlined by megablockbuster Revlimid, this big biotech is an oncology and autoimmune powerhouse's stock is showing no signs of slowing down.
Warren Buffett vs. His Worst Nightmare
Warren Buffett just called this emerging technology a "real threat" to his biggest cash-cow. While Buffett shakes in his billionaire-boots, only a few investors are embracing this new market which experts say will be worth over $2 trillion. It won't be long before everyone on Wall Street wises up, that's why The Motley Fool is releasing this timely investor alert. Click here to learn more about what's keeping Buffett up at night and the one public company we're calling the "brains behind" the technology.
Vote here to determine the winner of this match and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
The article Better Stock Today Challenge: Energy Transfer Partners vs. Celgene originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Joel South has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.